Open Access

Immunosuppressive effects of vascular endothelial growth factor (Review)

  • Authors:
    • Domenico Ribatti
  • View Affiliations

  • Published online on: September 1, 2022     https://doi.org/10.3892/ol.2022.13489
  • Article Number: 369
  • Copyright: © Ribatti et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vascular endothelial growth factor (VEGF) serves a critical role in vasculogenesis, angiogenesis, tumor, inflammatory angiogenesis and lymphangiogenesis. Since 2004, bevacizumab (Avastin), a humanized anti‑VEGFA monoclonal antibody, has been approved for the treatment of non‑small cell lung, breast, kidney and ovarian cancer in combination with standard chemotherapy. VEGF has been demonstrated to be important in the clinic as a therapeutic target in the anti‑angiogenic approach to cancer therapy. The targeting of VEGF, together with immunotherapy, has been reported to be able to reverse the immunosuppressive effects of VEGF. A positive correlation between VEGF expression and the reduced survival rates of patients with cancer has also been demonstrated. Furthermore, increased VEGF expression can lead to immune suppression via the inhibition of dendritic cell maturation, the reduction of T‑cell tumor infiltration and the promotion of inhibitory cell types in the tumor microenvironment.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ribatti D: Immunosuppressive effects of vascular endothelial growth factor (Review). Oncol Lett 24: 369, 2022
APA
Ribatti, D. (2022). Immunosuppressive effects of vascular endothelial growth factor (Review). Oncology Letters, 24, 369. https://doi.org/10.3892/ol.2022.13489
MLA
Ribatti, D."Immunosuppressive effects of vascular endothelial growth factor (Review)". Oncology Letters 24.4 (2022): 369.
Chicago
Ribatti, D."Immunosuppressive effects of vascular endothelial growth factor (Review)". Oncology Letters 24, no. 4 (2022): 369. https://doi.org/10.3892/ol.2022.13489